These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16007877)

  • 1. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
    Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
    Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
    Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
    Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodular lymphocyte-predominant Hodgkin's lymphoma.
    Nogovà L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
    Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
    Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
    Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.
    Bräuninger A; Wacker HH; Rajewsky K; Küppers R; Hansmann ML
    Cancer Res; 2003 Apr; 63(7):1644-51. PubMed ID: 12670918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
    Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
    Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
    von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
    Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hodgkin lymphoma. Classification and pathogenesis].
    Foss HD; Marafioti T; Stein H
    Pathologe; 2000 Mar; 21(2):113-23. PubMed ID: 10840817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
    Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
    J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
    Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
    J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.
    Appel BE; Chen L; Buxton AB; Hutchison RE; Hodgson DC; Ehrlich PF; Constine LS; Schwartz CL
    J Clin Oncol; 2016 Jul; 34(20):2372-9. PubMed ID: 27185849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment results of Hodgkin's lymphoma].
    Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
    Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
    J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.